Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStem™) in late-stage Type 2 Diabetes patients. The off-the-shelf, allogeneic cell therapy demonstrated an 80% efficacy rate in reducing insulin dependence and stabilizing hemoglobin A1c levels, with no serious adverse effects observed. The study, involving 20 patients, confirmed the safety and efficacy of CELZ-201 using the same infusion procedure as the company’s ongoing FDA-cleared Type 1 Diabetes clinical trial.
This development is a critical advancement in the treatment of late-stage Type 2 Diabetes, a disease affecting millions and often requiring intensive insulin management as it progresses. The positive results suggest CELZ-201 could become a valuable alternative for patients who may not be suitable candidates for autologous therapies or those requiring more effective disease management options. The therapy’s potential to significantly reduce insulin dependence and stabilize blood sugar levels could dramatically improve quality of life for these patients and potentially reduce the long-term complications associated with the disease.
The pilot study enrolled 20 patients, with 10 receiving CELZ-201 and 10 receiving optimized medical therapy. The 80% efficacy rate in the treatment group is a promising indicator of the therapy’s potential. The absence of serious adverse effects reinforces the therapy’s safety profile, a crucial factor for chronic conditions like diabetes. This data strengthens the company’s position in the diabetes treatment landscape, complementing its existing research in Type 1 Diabetes.
This success positions Creative Medical Technology to potentially expand the clinical application of CELZ-201 to a broader patient population, including those with late-stage Type 2 Diabetes. The positive data may attract further investment and accelerate the therapy’s clinical development and potential commercialization. Furthermore, the company’s success with this allogeneic cell therapy platform could have implications beyond diabetes, opening avenues for exploration in other therapeutic areas with significant unmet needs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
